Abstract
Breast cancer is the leading cause of death among non-smoking women and thus has been the focus of intensive research. It has been generally accepted that the deregulation of oncogenes or their regulators play a pivotal role in progression of this prevalent disease. For example, amplification and overexpression of a number of oncogenes has been observed in a proportion of primary breast cancer biopsies. More recently, there has also been reports of inactivation tumor supressor genes in human breast cancer. While there is compelling evidence for a role of these genes in breast cancer tumor progression due to limitations inherent in these studies it is difficult to establish a direct causal association between expression of a certain oncogene and tumor progression. For this reason many groups have employed the transgenic mouse as a model system to directly study effects of oncogene expression in the murine mammary gland. This review will attempt to highlight some of the important lessons and potential applications that have emerged from the study of oncogene expression in the mammary epithelium of transgenic mice. The utility of the transgenic system to assess the transforming potential of oncogenes, to investigate the multi-step nature of malignant progression, and to be used as models for therapeutic intervention will be discussed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Rassoulzadegan M, Cowie A, Carr A, Glaichenhaus N, Kamen R, Cuzin F: The roles of individual polyomavirus early proteins in oncogenic transformation. Nature 300: 713–718, 1982
Land H, Parada LF, Weinberg RA: Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304: 596–602, 1983
Huang HJ, Yee JK, Shew JY, Chen PL, Bookstein R, Friedmann T, Lee EY, Lee WH: Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242: 1563–1566, 1988
Hanahan D: Transgenic mice as probes into complex systems. Science 246: 1265–1275, 1989
Escot C, Theillet C, Lidereau R, Spyratos F, Champeme J, Gest J, Calahan R: Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Aci USA 83: 4834–4838, 1986
Varley JM, Swallow JE, Brammer WJ, Whittaker JL, Walker RA: Alterations to either c-erbB-2 (neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1: 423–430, 1987
Mariani-Costantini R, Escot C, Theillet C, Gentile A, Merlo G, Lidereau R, Callahan R: In situ c-myc expression and genomic status of c-myc locus in infiltrating ductal carcinomas of the breast. Cancer Res 48: 99–205, 1988
Ali IU, Merlo G, Callahan R, Lidereau R: The amplification unit on chromosome 11q13 in agressive primary human tumors entails the bcl 1, int-2 and hst loc: Oncogene Res 3: 89–92, 1988
Zhou DJ, Casey G, and Cline MJ: Amplification of human int-2 in breast cancers and squamus carcinomas. Oncogene 2: 279–282, 1988
King CR, Kraus MH, Aaronson SA: Amplification of a novel v-erbB-related gene in human mammary carcinoma. Science 229: 974–976, 1985
Yokota JK, Toyoshima T, Sugimura T, Yamamoto M, Terada M, Battifora H, Cline MJ: Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1: 765–766, 1986
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of HER/neu oncogene. Science 235: 177–82, 1987
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF: Studies of Her/c-erbB-2 proto-oncogene in human breast and ovarian cancer. Science 244: 707–712, 1989
van de Vijer M, van de Bersselaar R, Devilee P, Cornelisse C, Peyerse J, Nusse R: Amplification of the c-neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol 7: 2019–2023, 1987
van de Vijver WJ, Peterse MJ, Mooi JL, Wisman P, Lomans J, Dalesio O, Nusse R: Neu-protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319: 1239–1245, 1988
Ali IU, Campbell G, Lidereau R, Callahan R: Amplification of c-erbB-2 and aggressive breast tumors? Science 240: 1795–1798, 1988
Barnes DM, Lammie GA, Millis RR, Gullick WL, Allen DS, Altman DG: An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer 58: 448–452, 1988
Borg A, Tandon A, Sigurdsson H, Clark G, Ferno MF, Fuqua SAW, Killander D and McGuire WL: HER-2/neu amplification predicts poorer survival in node-positive breast cancer. Cancer Res 50: 4332–4337, 1990
Pattengale PK, Stewart T, Leder A, Sinn E, Muller W, Tepler I, Schmidt E, Leder P: Animal models of human disease: pathology and molecular biology of spontaneous neoplasms occurring in transgenic mice carrying and expressing activated cellular oncogenes. Am J Path 135: 39–61, 1989
Andres AC, Schonenberger B, Groner B, Hennighausen L, LeMeur M, Gerlinger P: Ha-ras oncogene expression directed by a milk protein gene promoter: Tissue specificity, hormonal regulation, and tumor induction in transgenic mice. Proc Natl Acad Sci 84: 1299–1303, 1987
Schonenberger CA, Andres C, Groner B, van der Valk MA, LeMeur M, Gerlinger P: Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumors with constitutive milk protein gene transcription. EMBO J 7: 169–175, 1988
Andres AC, van der Valk MA, Schonenberger CA, Fluckiger F, Lemeur M, Gerlinger P, Groner B: Ha-ras and c-myc oncogene expression interferes with morphological and functional differentiation of mammary epithelial cells in single and double transgenic mice. Genes and Dev 2, 1486–1495, 1988
Hunter T: Cooperation between oncogenes, Cell 64: 249–270, 1991
Stewart T, Pattengale PK, Leder P: Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 38: 627–637, 1984
Leder A, Pattengale PK, Kuo A, Stewart T and Leder P: Consequences of widespread deregulation of the c-myc gene in transgenic mice. Cell 45: 485–495, 1986
Sinn E, Muller W, Pattengale PK, Tepler I, Wallace R, Leder P: Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 49: 465–475, 1987
Zarbl HS, Sukumar S, Artur AV, Martin-Zanca D, Barbacid M: Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methyl urea during the initiation of mammary carcinogenesis in rats. Nature 315: 382–385
Sukumar S, Carney WP, Barbacid M: Independent molecular pathways in initiation and loss of hormone responsiveness of breast carcinomas. Science 240: 524–526, 1988
Tremblay P, Pothier F, Hoang T, Tremblay G, Brownstein S, Liszauer A, Jolicoeur P: Transgenic mice carrying the mouse mammary tumor virus ras fusion gene: distinct effects in various tissues. Mol Biol Cell 9: 854–859
Mangues R, Seidman I, Pellicer A, Gordon JW: Tumorigenesis and male sterility in transgenic mice expressing MMTV/N-ras oncogene. Oncogene 5: 1491–1497, 1990
Muller WJ, Lee FS, Dickson C, Peters G, Pattengale P, Leder P: The int-2 gene product acts as an epithelial growth factor in transgenic mice EMBO J 9, 907–913, 1990
Nussensweig MC, Schmidt E, Shaw AC, Sinn E, Campos-Torres J, Mathey-Prevot B, Pattengale PK, Leder P: A human immunoglobulin gene reduces the incidence of lymphomas in c-myc-bearing transgenic mice. Nature 336: 446–450, 1988
Nusse R, Brown A, Papkoff J, Scambler P, Scackleford G, McMahon A, Moon R, Varmus H: A new nomenclature for int-1 and related genes: The Wnt gene family. Cell 64: 231–232, 1991
Nusse R: The int genes in mammary tumorigenesis and in normal development. Trends Genet 4: 291–295
Nusse R, van Ooyen A, Cos D, Fung YK, Varmus HE: Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature 307: 131–136, 1984
van Ooyen A, Nusse R: Structure and nucleotide sequence of the putative mammary oncogene int-1: proviral insertions leave the protein-encoding domain intact. Cell 39: 233–240, 1984
Moore R, Casey G, Brookes S, Dixoon M, Peters G, Dickson C: Sequence, topography and protein coding potential of mouse int-2: a putative oncogene activated by mouse mammary tumor virus. EMBO J 5: 919–924, 1986
Nusse R, Varmus HE: Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31: 99–109, 1982
Jakobovits A, Schakleford GM, Varmus HE, Martin GR: Two proto-oncogenes implicated in mammary carcinogenesis, int-1 and int-2, are independently regulated during mouse development. Proc Natl Acad Sci 83: 7806–7810, 1986
Shackleford G, Varmus HE: Expression of the proto-oncogene int-1 is restricted to postmeiotic male germ cells and the neural tube of mid-gestational embryos. Cell 50: 89–95, 1987
Wilkinson DG, Bailes JA, McMahon A: Expression of the proto-oncogene int-1 is restricted to specific neural cells in the developing embryo. Cell 50: 79–88, 1987
Brown AMC, Wildin RS, Prendergast T, Varmus HE: A retrovirus vector expressing the putative mammary oncogene int-1 causes partial transformation of a mammary epithelial cell line. Cell 46: 1001–1009, 1986
Tsukamoto AS, Grossschedl R, Guzman RC, Parslow T, Varmus HE: Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 55: 619–625, 1988
Gavin BJ, McMahon JA, McMahon AP: Expression of multiple novel Wnt-1/int-1-related genes during fetal and adult mouse development. Genes and Dev 4: 2319–2332, 1990
Wilkinson DG, Peters G, Dickson C, McMahon A: Expression of the FGF-related proto-oncogene int-2 during gastrulation and neuralation in the mouse. EMBO J 7: 691–695, 1988
Wilkinson DG, Bhatt S, McMahon AP: Expression pattern of the FGF-related proto-oncogene int-2 suggests multiple roles during fetal development. Development 105: 131–136, 1989
Abraham JA, Whang JL, Tumulo A, Mergia A, Friedman J, Gospodarwicz D, Fiddes JC: Human basic fibroblast growth factor: nucleotide sequence and genomic organization. EMBO J 5: 2523–2528
Deli Bovi P, Basilico C: Isolation of a rearranged human transforming gene following transfection of Kaposi sarcoma DNA. Proc Natl Acad Sci USA 84: 5660–5664, 1987
Dickson C, Peters G: Potential oncogene product related to growth factors. Nature 326: 833, 1987
Yoshida TK, Miyagawa K, Odagiri H, Sakamoto H, Little PFR, Terada M, Sigimura T: Genomic sequence of hst, a transforming gene encoding a protein homologous to fibroblast growth factors and the int-2-encoded protein. Proc Natl Acad Sci USA 84: 7305–7309, 1987
Zhan X, Bates B, Hu X, Golfarb M: The human FGF-5 oncogene encodes a novel protein related to fibroblast growth factors. Mol Cell Biol 8: 3487–3495, 1988
Ornitz DM, Moreadith RW, Leder P: Binary system for regulating transgene expression in mice: targeting int-2 gene expression with yeast GAL4/UAS control elements. Proc Natl Acad Sci USA 88: 698–702, 1991
Stewart TA, Hollingshead PG, Pitts SL: Multiple regulatory domains in the mouse mammary tumor virus long terminal repeat revealed by analysis of fusion genes in transgenic mice. Mol Cell Biol 8: 473–479, 1988
Liu SC, Sanfilippo B, Perroteau I, Derynck R, Salomon DS, Kidwell WR: Expression of transforming growth factor α (TGF α) in differentiated rat mammary tumors: estrogen induction of TGF α production. Mol Endocrinol 1: 683–692, 1987
Valverius EM, Bates SE, Stampher MR, Clark R, McCormick, Salomon DS, Lippman ME, Dickson RB: Transforming growth factor α production and epidermal growth factor receptor expression in normal and oncogene transformed human mammary epithelial cells. Mol Endocr 3: 203–214
Matsui Y, Halter SA, Holt JT, Hogan BLM, Coffey RJ: Development of mammary hyperplasia and neoplasia in MMTV-TGF α transgenic mice. Cell 61: 1147–1155, 1990
Jhappan C, Stahle C, Harkins RN, Fausto N, Smith GH, Merlino GT: TGF α overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 61: 1137–1146, 1990
Sandgren EP, Luetteke NC, Palmiter RD, Brinster R, Lee DC: Overexpression of TGF α in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61: 1121–1135, 1990
Bargmann CI, Hung MC, Weinberg RA: Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45: 649–657, 1986
Muller WJ, Sinn E, Wallace R, Pattengale PK, Leder P: Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54: 105–115, 1988
Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P: Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57: 931–936, 1989
Suda Y, Aizawa S, Furuta Y, Yagi T, Ikawa Y, Saitoh K, Yamada Y, Toyoshima K, Yamamoto T: Induction of variety of tumors by c-erbB-2 and clonal nature of lymphomas even with the mutated gene (Val 659-Glu 659). EMBO J 9: 181–190, 1990
Iwamoto T, Takahashi M, Ito M, Hamaguchi M, Isobe KI, Misawa N, Asai JP, Yoshida T, Nakashima: Oncogenicity of ret transforming gene in MMTV/ret transgenic mice. Oncogene 5: 535–542, 1990
Lemoine NR, Staddon S, Dickson C, Barnes DM, Gullick WJ: Absence of transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene 5: 237–239, 1990
Lee E, To P, Shew JY, Bookstein R, Scully P, Lee WH: Inactivation of human retinoblastoma susceptibility gene in human breast cancers. Science 241: 218–221, 1988
T'ang A, Varley JM, Chakraborty S, Murphree AL, Fung T: Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science 242: 263–266, 1988
Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH: Germline mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 250: 1233–1238, 1990
Srivastava S, Zou Z, Pirollo K, Blattner W, Chang EH: Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348: 747–749, 1990
DeCaprio JA, Ludlow JW, Figge J, Shew J-W, Huang CM, Lee WH, Marslio E, Pauch E, Livingston D: SV 40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility. Cell 54: 275–283, 1988
Whyte P, Buchkovich K, Horowitz JM, Friend S, Raybuck M, Wienberg RA, Harlow E: Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 334: 124–129, 1988
Choi Y, Lee I, Ross SR: Requirement for the simian virus 40 small tumor antigen in tumorigenesis in transgenic mice. Mol Cell Biol 8: 3382–3390, 1988
Koike K, Hinrichs SH, Isselbacher KJ, Jay G: Transgenic mouse model for human gastric carcinoma. Proc Natl Acad Sci 86: 5615–5619, 1989
van Lohuizen MA, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T, Berns A: Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukaemia virus-induced tumors. Cell 56: 673–682, 1989
Verbeek S, van Lohuizen M, van der Valk MA, Domen J, Kraal G, Berns A: Mice bearing the Eu-myc and Eu pim-1 develop pre-B-cell Leukaemia prenatally. Mol Cell Biol 11: 1176–1179.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Muller, W.J. Expression of activated oncogenes in the murine mammary gland: transgenic models for human breast cancer. Cancer Metast Rev 10, 217–227 (1991). https://doi.org/10.1007/BF00050793
Issue Date:
DOI: https://doi.org/10.1007/BF00050793